Healthcare stocks are experiencing a downturn, but there are still opportunities to be found. While Eli Lilly, a leader in GLP-1 weight loss drugs, boasts a high price-to-earnings ratio of 46, two other drugmakers offer more attractive options for investors. These competitors have price-to-earnings ratios that are less than half of Eli Lilly's, and their dividend yields are significantly higher, reaching up to 6.3%. This makes them appealing to value-oriented investors or those seeking stable income. However, it's important to note that Eli Lilly's strong performance in 2025, with Mounjaro and Zepbound sales soaring, sets a high bar for its competitors. Novo Nordisk, for instance, saw only a 31% growth in its obesity drugs, and its stock price has taken a hit, down 66% since mid-2024. This could be a buying opportunity for long-term value investors, as the P/E ratio is 13 and the dividend yield is well-covered. Pfizer, on the other hand, is playing catch-up with its GLP-1 drug candidate. While it may not be leading the pharmaceutical sector right now, its history of innovation and success in other areas, such as oncology and migraine treatments, make it a potential turnaround story. However, the Motley Fool Stock Advisor team recently identified 10 stocks with monster return potential, and Pfizer was not one of them. So, while healthcare stocks are sinking, there are still opportunities to be found, but it's important to do your research and consider your investment goals and risk tolerance before making any decisions.
